Search company, investor...
Search

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

orionisbio.com

Stage

Series A | Alive

Total Raised

$24.5M

Last Raised

$19.72M | 4 yrs ago

About Orionis Biosciences

Orionis Biosciences is a stealth biotechnology company.

Orionis Biosciences Headquarters Location

Newton, Massachusetts,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Orionis Biosciences Patents

Orionis Biosciences has filed 27 patents.

The 3 most popular patent topics include:

  • Immune system
  • Transcription factors
  • Immunology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/27/2020

9/13/2022

Clusters of differentiation, Transcription factors, Immune system, Immunology, Monoclonal antibodies

Grant

Application Date

3/27/2020

Grant Date

9/13/2022

Title

Related Topics

Clusters of differentiation, Transcription factors, Immune system, Immunology, Monoclonal antibodies

Status

Grant

Latest Orionis Biosciences News

Project Helios launched to unlock new approaches in small molecule drug discovery

Mar 10, 2021

The University of Texas MD Anderson Cancer Center's Therapeutics Discovery division and Orionis Biosciences today announced the launch of Project Helios, a research collaboration designed to unlock new drug development opportunities through genome-scale mapping of drug-target interactions. Combining Orionis' unique high-throughput drug discovery technologies with the Therapeutics Discovery division's expertise in small-molecule therapies and translational biology, Project Helios aims to create an unparalleled collection of drug-target interaction data to enable rational drug discovery, optimization and repurposing. The project will focus initially on developing therapies for unmet needs in oncology, with the possibility of expanding to additional therapeutic areas in the future. Related Stories "We are excited to be collaborating with MD Anderson's Therapeutics Discovery team in launching Project Helios, a fundamental step toward new approaches in drug discovery that will enlighten our understanding of the dark proteome. This effort will build on a wealth of public data, chemical and clinical knowledge that has been assembled over many years across the pharmaceutical industry and biomedical institutions," said Niko Kley, chief executive officer at Orionis. Molecular interactions between small-molecule drugs and proteins define both their therapeutic efficacy as well as undesired adverse effects. A comprehensive unraveling of these interactions is fundamentally important both for illuminating new drug development opportunities and devising safer medicines with fewer related toxicities. "We are pleased to be collaborating with Orionis on this exciting initiative to understand drug-target interactions at a new level of detail. The intersection of the data from Project Helios with the unparalleled translational research and drug discovery capabilities at MD Anderson should yield important insights for therapeutics development, hopefully resulting in impactful new medicines for patients with cancer," said Philip Jones, Ph.D., vice president of Therapeutics Discovery at MD Anderson. Project Helios will conduct systematic and unbiased mapping of drug interactions across the human proteome with a large portfolio of bioactive, chemically diverse small molecules, including experimental and approved drugs. The findings may provide opportunities to repurpose approved therapies, optimize therapeutic approaches for known targets and develop therapies for novel targets. "We expect Project Helios to generate a unique data set for the application of new machine-learning models for multivariate, genomic-scale drug design and to further illuminate what we refer to as the 'Drug Pocketome' [small-molecule binding sites on drug targets]," said Riccardo Sabatini, chief data scientist at Orionis. Source:

Orionis Biosciences Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Orionis Biosciences Rank

  • Where is Orionis Biosciences's headquarters?

    Orionis Biosciences's headquarters is located at Newton.

  • What is Orionis Biosciences's latest funding round?

    Orionis Biosciences's latest funding round is Series A.

  • How much did Orionis Biosciences raise?

    Orionis Biosciences raised a total of $24.5M.

  • Who are the investors of Orionis Biosciences?

    Investors of Orionis Biosciences include Excel Venture Management.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.